Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Mikyung Chang"'
Autor:
Mikyung Chang
Publikováno v:
Korean Linguistics. 94:1-29
Autor:
Andrew J. Peacock, Pavel Jansa, Carmine Dario Vizza, Stephan Rosenkranz, Paul A. Corris, Robert E. White, Hikmet Al-Hiti, Gérald Simonneau, Raymond L. Benza, Jaquelina S. Ota-Arakaki, J. Simon R. Gibbs, Tomás Pulido, Hossein Ardeschir Ghofrani, Karen Paraschin, Gisela Meyer, Anton Vonk Noordegraaf, James R. Klinger, Sung A. Chang, Ekkehard Grünig, Frank Kleinjung, David Langleben, Mikyung Chang, Vallerie V. McLaughlin, Christian Meier, Marius M. Hoeper
Publikováno v:
Chest. 158:A2156-A2159
Autor:
Marius M Hoeper, Hikmet Al-Hiti, Raymond L Benza, Sung-A Chang, Paul A Corris, J Simon R Gibbs, Ekkehard Grünig, Pavel Jansa, James R Klinger, David Langleben, Vallerie V McLaughlin, Gisela M B Meyer, Jaquelina Ota-Arakaki, Andrew J Peacock, Tomás Pulido, Stephan Rosenkranz, Carmine Dario Vizza, Anton Vonk-Noordegraaf, R James White, Mikyung Chang, Frank Kleinjung, Christian Meier, Karen Paraschin, Hossein Ardeschir Ghofrani, Gérald Simonneau, H Olschewski, M Delcroix, M Andrade-Lima, R de Amorim Corrêac, F Figueiredo Campos, J Ota Arakaki, G Meyer, R De Souza, D Langleben, H Al-Hiti, P Jansa, S Mellemkjær, F Bauer, D Montani, G Simonneau, D Drömann, H-A Ghofrani, E Grünig, M Halank, M Held, MM Hoeper, H Klose, N Kneidinger, H Leuchte, C Opitz, S Rosenkranz, H Wilkens, H Wirtz, H Karvounis, G Pitsiou, S Orfanos, M D'Alto, S Ghio, CD Vizza, P Vitulo, T Nakayama, H Maki, S Tatebe, M de los Rios Ibarra, T Pulido, A Van Dijk, A Vonk-Noordegraaf, T Roleder, G Castro, MJ Loureiro, S Robalo-Martins, JA Barberá, M Lázaro, GM Perez-Penate, A Román, C-C Cheng, C-H Hsu, H-H Hsu, E Atahan, N Mogulkoc Bishop, NG Okumus, Z Onen, H-J Chang, S-A Chang, J-S Lee, H-K Kim, JG Coghlan, PA Corris, AC Church, R Condliffe, JSR Gibbs, AJ Peacock, S Wort, R Allen, S Allen, R Awdish, RL Benza, S DeSouza, J Feldman, S Johri, JR Klinger, D Layish, J McConnell, VV McLaughlin, C Migliore, F Rahaghi, F Rischard, I Robbins, L Satterwhite, T Shah, R Sulica, RJ White
Publikováno v:
The Lancet Respiratory Medicine, 9(6), 573-584. Elsevier Limited
Hoeper, M M, Al-Hiti, H, Benza, R L, Chang, S-A, Corris, P A, Gibbs, J S R, Grünig, E, Jansa, P, Klinger, J R, Langleben, D, McLaughlin, V V, Meyer, G M B, Ota-Arakaki, J, Peacock, A J, Pulido, T, Rosenkranz, S, Vizza, C D, Vonk-Noordegraaf, A, White, R J, Chang, M, Kleinjung, F, Meier, C, Paraschin, K, Ghofrani, H A, Simonneau, G & The REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE) : a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
Hoeper, M M, Al-Hiti, H, Benza, R L, Chang, S-A, Corris, P A, Gibbs, J S R, Grünig, E, Jansa, P, Klinger, J R, Langleben, D, McLaughlin, V V, Meyer, G M B, Ota-Arakaki, J, Peacock, A J, Pulido, T, Rosenkranz, S, Vizza, C D, Vonk-Noordegraaf, A, White, R J, Chang, M, Kleinjung, F, Meier, C, Paraschin, K, Ghofrani, H A, Simonneau, G & The REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE) : a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
REPLACE investigators 2021, ' Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 6, pp. 573-584 . https://doi.org/10.1016/S2213-2600(20)30532-4
BACKGROUND: Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56129be8d7d9bbfecf556d9b7ae7f504
https://research.vumc.nl/en/publications/422b5ce8-53f9-4f2f-8e03-8a80ae3dd2b8
https://research.vumc.nl/en/publications/422b5ce8-53f9-4f2f-8e03-8a80ae3dd2b8
Autor:
Gérald Simonneau, Pavel Jansa, Stephan Rosenkranz, Hossein Ardeschir Ghofrani, Anton Vonk-Noordegraaf, Ekkehard Grünig, Hikmet Al-Hiti, Sung-A Chang, Frank Kleinjung, Karen Paraschin, David Langleben, James R. Klinger, Paul A. Corris, Gisela Meyer, Tomás Pulido, Andrew J. Peacock, Marius M. Hoeper, James R. White, Christian Meier, MiKyung Chang, Simon Gibbs, Vallerie V. McLaughlin, Raymond L. Benza, Jaquelina S. Ota-Arakaki, Dario Vizza
Publikováno v:
Pulmonary hypertension.
Background: Pulmonary arterial hypertension (PAH) treatment guidelines recommend patients achieve/maintain a low-risk profile. Many patients treated with PAH-targeted therapy do not meet this treatment goal. Aim: Compare switching to riociguat (RIO)
Autor:
Jens Klotsche, G. Simonneau, E. Grueig, MiKyung Chang, J.A. Barberà, Stephan Rosenkranz, Pavel Jansa, Marc Humbert, Marius M. Hoeper, Henning Gall
Publikováno v:
C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION.
Autor:
David Langleben, Frank Kleinjung, Stephan Rosenkranz, Marius M. Hoeper, Christian Meier, Paul A. Corris, Raymond L. Benza, MiKyung Chang, Gérald Simonneau, Hossein Ardeschir Ghofrani
Publikováno v:
The Journal of Heart and Lung Transplantation. 40:S465
Purpose The REPLACE study showed that switching to riociguat (rio) can benefit pulmonary arterial hypertension (PAH) patients treated with phosphodiesterase type 5 inhibitors (PDE5i) but still at intermediate risk. Improvements to lower risk status w
Autor:
Lisa Mielniczuk, Mauricio Orozco-Levi, Ekkehard Grünig, Kai Vogtländer, Michael Halank, Nobuhiro Tanabe, MiKyung Chang, Henning Gall, Jean-Luc Vachiery
Publikováno v:
Lung. 196(3)
A proportion of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) do not achieve treatment goals or experience side effects on their current therapy. In such cases, switching patients to a n
Autor:
Dennis Busse, Marius M. Hoeper, James R. Klinger, J. Gerry Coghlan, David Langleben, Raymond L. Benza, Gérald Simonneau, Michael Halank, Robert Naeije, Christian Meier, Paul A. Corris, Pablo Colorado, Mikyung Chang, Carmine Dario Vizza, Alistair C. Church
Publikováno v:
Chest. 152:A1002-A1003
Autor:
Lisa Mielniczuk, Kai Vogtländer, Nobuhiro Tanabe, Jean-Luc Vachiery, Michael Halank, Ekkehard Grünig, MiKyung Chang, Mauricio Orozco-Levi, Henning Gall
Publikováno v:
Lung
Purpose A proportion of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) do not achieve treatment goals or experience side effects on their current therapy. In such cases, switching patient
Autor:
G. Simonneau, Hubert Wirtz, MiKyung Chang, Robert Naeije, Pablo Colorado, David Langleben, Christian Meier, M. Patarroyo-Aponte, Paul A. Corris, Carmine Dario Vizza, Raymond L. Benza, Marius Hoeper, James R. Klinger, Dennis Busse
Publikováno v:
The Journal of Heart and Lung Transplantation. 37:S152